THER-13. IMMUNOTHERAPY VERSUS STANDARD OF CARE IN MELANOMA BRAIN METASTASES WITH KNOWN BRAF STATUS

BACKGROUND: A mutation of the BRAF protein is seen in approximately 50% of melanoma patients. Immune checkpoint inhibitors (ICI) are standard therapy in melanoma patients independent of a patient’s BRAF status. The primary objective of this study is to investigate the impact of BRAF status in patien...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neurooncol Adv
Glavni autori: Barnett, Addison, Sagar, Soumya, Lauko, Adam, Wei, Wei, Chao, Samuel, Peereboom, David, Stevens, Glen, Angelov, Lilyana, Yu, Jennifer, Murphy, Erin, Mohammadi, Alireza, Suh, John, Barnett, Gene, Ahluwalia, Manmeet
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2019
Teme:
Abstracts
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7213394/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdz014.056
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items